A resolution designating May 2026 as "ALS Awareness Month".

Summary of S. Res. 751 (119th Congress) – Designating May 2026 as “ALS Awareness Month”

Purpose

• Designate May 2026 as “ALS Awareness Month.”
• Express Senate commitment to improving care, accelerating research, and reducing the burden of amyotrophic lateral sclerosis (ALS) for patients and families.

Key Provisions and Provisions of the Resolution

• Designation:
  • Officially designates May 2026 as “ ALS Awareness Month.”
• Senate’s stated dedication and goals:
  • Ensure individuals with ALS have access to effective treatments and high-quality services and supports as early as possible after diagnosis.
  • Identify risk factors and causes of ALS to prevent new cases.
  • Empower individuals with ALS to maintain maximum personal independence.
  • Reduce the physical and emotional burdens of living with ALS.
• Commendation:
  • Recognizes and commends the dedication of spouses, children, family members, friends, organizations, volunteers, researchers, and caregivers across the United States who work to improve the quality and length of life for ALS patients and to develop treatments and cures available to patients as soon as possible.

Background/Context Included in the Resolution

• ALS is described as a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord.
• Typical life expectancy after diagnosis ranges from 2 to 5 years.
• ALS affects individuals worldwide without racial, ethnic, gender, or socioeconomic boundaries.
• Most cases have unknown causes (up to 90%), with about 10% having a strong genetic driver.
• The disease commonly presents with muscle weakness or stiffness and progresses to affect muscles controlling limbs, trunk, speech, swallowing, and breathing.
• Average diagnostic delay is more than one year from symptom onset.
• In the U.S., tens of thousands live with ALS at any given time; more than 5,000 new diagnoses annually (about 15 per day); and a death or new diagnosis occurs approximately every 90 minutes.
• Veterans are disproportionately affected compared with non-veterans.
• No cure exists as of the date of introduction.

Who and What Would Be Affected

• Individuals diagnosed with ALS and their families/caregivers (for considerations of care, support, and financial burden).
• Healthcare providers, researchers, patient advocacy organizations, and policymakers involved in ALS care, research, and services.
• The resolution signals Congressional intent to prioritize ALS-related policies within the broader public health and medical research landscape.

Procedural/Timelines

• Introduced in the Senate on May 21, 2026.
• Referred to the Senate Committee on the Judiciary.
• As a concurrent resolution or Senate resolution, it does not propose new funding or enforceable mandates but expresses the sense of the Senate and designates a commemorative month.
• No specific implementation timeline or funding authorization is included; the resolution serves to raise awareness and reaffirm priorities.

Practical Impact

• Symbolic designation that can help raise public awareness about ALS.
• Signals bipartisan support for early access to treatments, enhanced patient services, and accelerated research into causes and cures.
• May inform advocacy efforts, awareness campaigns, and related legislative priorities without creating new legal obligations or spending.